title: Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  To investigate the effects of the dosage of anticancer agents during transcatheter arterial chemoembolization (TACE) on the T cell subsets in patients with hepatocellular carcinoma (HCC).
  
  
  METHODS
  Thirty-six patients with unresectable HCC were randomly divided into 2 groups to receive superselective TACE. Patients in group A (n=18) received low-dose (2-4 mg) mitomycin C (MMC) as the anticancer drug when the tumor was less than 5 cm in diameter; when the tumor ranged from 5 and 8 cm in diameter, 4-6 mg MMC along with 10 mg epirubicin (EPI) was given, and in cases of even larger tumors, 6-8 mg MMC, 10 mg EPI and 100 mg CBP were prescribed. Conventional chemotherapy regimen constituted by 10 mg MMC, 40 mg PI and 300 mg CBP was adopted in group B (n=18). The peripheral blood T cell subsets including CD3(+), CD4(+), CD8(+), NK, CD4(+)/CD8(+) ratio, CD4(+)CD45(+), CD4(+)CD29(+), CD8(+)CD28(+) and CD8(+)CD28- were measured by flow cytometry in both groups before and one week after treatment.
  
  
  RESULTS
  The T cell subsets were comparable in the 2 groups before the treatment. After TACE, no significant changes occurred in CD3(+), CD4(+), CD8(+), NK, CD4(+)/CD8(+), CD4(+)CD29(+) or CD8(+)CD28- cells in group A, while significant decrease in CD4(+)CD45(+) and increase in CD8(+)CD28(+) cells were observed (P<0.05 and P<0.001, respectively). In group B, CD4(+) and CD4(+)CD29(+) levels, together with CD4(+)/CD8(+) ratio, were significantly lower than those before treatment (P<0.05), but CD8(+) and CD8(+)CD28- subsets were significantly higher (P<0.05).
  
  
  CONCLUSIONS
  The cellular immune function of HCC patients is significantly impaired by anticancer drugs for TACE at conventional dose, while low-dose of the drugs may enhance the cellular immune function.
authors.affiliation: Department of Interventional Radiology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. luwei@fimmu.edu.cn
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Yan-Hao
authors.initials: YH
authors.lastname: Li
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: He
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
authors.forename: Qing-Le
authors.initials: QL
authors.lastname: Zeng
authors.forename: Yu-Rong
authors.initials: YR
authors.lastname: Qiu
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000145:classification
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D016685:Mitomycin